Free tool
FAERS Monitor: Emsam
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021336 or its brand name (Emsam, Selegiline). Reports on generic versions are filed under their own applications.
Reports
2,999
Serious
1,411
47% of reports
Hospitalization
598
Death reported
174
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective329
- insomnia189
- application site erythema183
- hallucination171
- dizziness170
- fall147
- dyskinesia140
- drug interaction135
- anxiety128
- depression128
- application site rash127
- tremor121
- application site pruritus120
- confusional state118
- fatigue115
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 35 |
| 2007 | 311 |
| 2008 | 27 |
| 2009 | 43 |
| 2010 | 34 |
| 2011 | 203 |
| 2012 | 182 |
| 2013 | 145 |
| 2014 | 51 |
| 2015 | 199 |
| 2016 | 194 |
| 2017 | 224 |
| 2018 | 174 |
| 2019 | 195 |
| 2020 | 193 |
| 2021 | 165 |
| 2022 | 129 |
| 2023 | 147 |
| 2024 | 112 |
| 2025 | 132 |
| 2026 | 100 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,160 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site rashSignal | 127 | 65.4 | 55.1 | 7,917 |
| application site erythemaSignal | 183 | 49.3 | 42.8 | 8,563 |
| application site pruritusSignal | 120 | 37.3 | 31.3 | 4,184 |
| dyskinesiaSignal | 140 | 24.2 | 20.6 | 3,091 |
| hallucinationSignal | 171 | 15.9 | 13.8 | 2,384 |
| drug interactionSignal | 135 | 6.0 | 5.1 | 558 |
| confusional stateSignal | 118 | 5.1 | 4.3 | 390 |
| tremorSignal | 121 | 5.1 | 4.3 | 399 |
| insomniaSignal | 189 | 5.0 | 4.3 | 604 |
| depressionSignal | 128 | 3.9 | 3.3 | 282 |
| anxietySignal | 128 | 3.2 | 2.7 | 189 |
| fallSignal | 147 | 3.1 | 2.6 | 210 |
| dizzinessSignal | 170 | 2.4 | 2.1 | 139 |
| drug ineffective | 329 | 1.8 | 1.6 | 112 |
| fatigue | 115 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.